$ACAD
ACADIA PHARMACEUTICALS INC

2014 Q2 Form 10-Q Financial Statement

#000119312514184864 Filed on May 06, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q4
Revenue $28.00K $30.00K $37.00K
YoY Change -93.79% -92.81% -90.26%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.000M $6.300M $4.300M
YoY Change 220.0% 186.36% 86.96%
% of Gross Profit
Research & Development $13.80M $11.67M $7.900M
YoY Change 94.02% 163.39% 61.22%
% of Gross Profit
Depreciation & Amortization $50.00K $43.00K $40.00K
YoY Change 258.33% 100.0%
% of Gross Profit
Operating Expenses $21.75M $17.99M $12.20M
YoY Change 126.38% 173.33% 69.44%
Operating Profit -$21.72M -$17.96M
YoY Change 137.23% 191.34%
Interest Expense $228.0K $130.0K $100.0K
YoY Change 200.0% 217.07%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$21.50M -$17.80M -$12.00M
YoY Change 136.26% 191.8% 76.47%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.50M -$17.83M -$12.05M
YoY Change 136.7% 191.16% 76.93%
Net Earnings / Revenue -76767.86% -59426.67% -32564.86%
Basic Earnings Per Share
Diluted Earnings Per Share -$205.2K -$191.4K -$131.9K
COMMON SHARES
Basic Shares Outstanding 98.98M shares 91.35M shares 90.87M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $354.5M $369.3M $185.8M
YoY Change 72.52% 263.83% 72.08%
Cash & Equivalents $13.70M $96.46M $11.71M
Short-Term Investments $340.8M $272.8M $174.1M
Other Short-Term Assets $3.100M $1.900M $1.800M
YoY Change 138.46% 26.67% 200.0%
Inventory
Prepaid Expenses $1.893M $1.820M
Receivables
Other Receivables
Total Short-Term Assets $358.9M $372.8M $188.4M
YoY Change 73.56% 262.01% 73.53%
LONG-TERM ASSETS
Property, Plant & Equipment $500.0K $543.0K $579.0K
YoY Change 443.48% 1710.0% 1278.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $111.0K $143.0K $179.0K
YoY Change 98.21%
Total Long-Term Assets $611.0K $686.0K $758.0K
YoY Change 312.84% 2186.67% 1704.76%
TOTAL ASSETS
Total Short-Term Assets $358.9M $372.8M $188.4M
Total Long-Term Assets $611.0K $686.0K $758.0K
Total Assets $359.5M $373.5M $189.1M
YoY Change 73.73% 262.57% 74.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.104M $1.562M $372.0K
YoY Change -6.2% 11.89% -72.95%
Accrued Expenses $8.206M $6.429M $6.552M
YoY Change 26.48% 54.58% 58.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.339M $8.033M $6.979M
YoY Change 20.1% 41.05% 17.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Total Long-Term Liabilities $18.00K $13.00K $8.000K
YoY Change -99.9% -99.93% -99.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.339M $8.033M $6.979M
Total Long-Term Liabilities $18.00K $13.00K $8.000K
Total Liabilities $9.357M $8.046M $6.987M
YoY Change -63.16% -65.62% 17.47%
SHAREHOLDERS EQUITY
Retained Earnings -$445.0M -$423.5M -$405.7M
YoY Change 16.21% 13.28% 10.32%
Common Stock $10.00K $10.00K $9.000K
YoY Change 25.0% 42.86% 28.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $350.1M $365.5M $182.1M
YoY Change
Total Liabilities & Shareholders Equity $359.5M $373.5M $189.1M
YoY Change 73.73% 262.57% 74.16%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q4
OPERATING ACTIVITIES
Net Income -$21.50M -$17.83M -$12.05M
YoY Change 136.7% 191.16% 76.93%
Depreciation, Depletion And Amortization $50.00K $43.00K $40.00K
YoY Change 258.33% 100.0%
Cash From Operating Activities -$16.97M -$14.18M -$10.27M
YoY Change 211.95% 115.34% 63.28%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $6.000K -$130.0K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$67.51M -$99.11M $9.670M
YoY Change -31.5% 199.52% -127.58%
Cash From Investing Activities -$67.51M -$99.11M $9.550M
YoY Change -31.54% 199.55% -127.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $196.8M
YoY Change 94515.38%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.720M 198.0M 630.0K
YoY Change -98.43% 95111.54% -99.31%
NET CHANGE
Cash From Operating Activities -16.97M -14.18M -10.27M
Cash From Investing Activities -67.51M -99.11M 9.550M
Cash From Financing Activities 1.720M 198.0M 630.0K
Net Change In Cash -82.76M 84.75M -90.00K
YoY Change -1521.99% -314.76% -100.18%
FREE CASH FLOW
Cash From Operating Activities -$16.97M -$14.18M -$10.27M
Capital Expenditures $0.00 $6.000K -$130.0K
Free Cash Flow -$16.97M -$14.19M -$10.14M
YoY Change 215.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98835635 shares
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8033000
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1265000
CY2014Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
104000
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
788946000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1562000
CY2014Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
753000
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
98976326 shares
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18436000
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98835635 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
365460000
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-423496000
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
42000
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6429000
CY2014Q1 us-gaap Liabilities
Liabilities
8046000
CY2014Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
13000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
10000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
373506000
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
143000
CY2014Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1893000
CY2014Q1 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
275598000
CY2014Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
272830000
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
543000
CY2014Q1 us-gaap Assets
Assets
373506000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96455000
CY2014Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
275601000
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
35200000
CY2014Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
369223000
CY2014Q1 us-gaap Assets Current
AssetsCurrent
372820000
CY2014Q1 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
4307000
CY2014Q1 acad Interest And Other Receivables
InterestAndOtherReceivables
1642000
CY2014Q1 acad Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
59000
CY2014Q1 acad Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
62000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57899000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91102618 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91102618 shares
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6979000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
48000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1865000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
172000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
587742000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
372000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
308000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
182131000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-405668000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
55000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6552000
CY2013Q4 us-gaap Liabilities
Liabilities
6987000
CY2013Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189118000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
179000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1820000
CY2013Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
174083000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
174083000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
579000
CY2013Q4 us-gaap Assets
Assets
189118000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11707000
CY2013Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
174038000
CY2013Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
185831000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
188360000
CY2013Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
4207000
CY2013Q4 acad Interest And Other Receivables
InterestAndOtherReceivables
750000
CY2013Q4 acad Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
59000
CY2013Q4 acad Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
14000
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7360000 shares
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
196800000
CY2013 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6585000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78748000 shares
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10718000 shares
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2013Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2013Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
54867000
CY2013Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
41000
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
180000
CY2013Q1 us-gaap Revenues
Revenues
417000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6112000
CY2013Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
7000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6164000
CY2013Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
761000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-6123000
CY2013Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-145000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
208000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2151000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
582000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-39463000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-33086000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
6581000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-294000
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
20000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
208000
CY2013Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000
CY2013Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21773000
CY2013Q1 us-gaap Depreciation
Depreciation
12000
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4430000
CY2014Q1 dei Trading Symbol
TradingSymbol
ACAD
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001070494
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14182000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92968000 shares
CY2014Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-36000
CY2014Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
150921000
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9645000 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-48000
CY2014Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
130000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
892000
CY2014Q1 us-gaap Revenues
Revenues
30000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17876000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-17958000
CY2014Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
73000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-17828000
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-311000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
198042000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6320000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3162000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
84748000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-99112000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
17988000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-13000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-123000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1190000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
198042000
CY2014Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
5000
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
51815000
CY2014Q1 us-gaap Depreciation
Depreciation
43000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11668000
CY2014Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0

Files In Submission

Name View Source Status
0001193125-14-184864-index-headers.html Edgar Link pending
0001193125-14-184864-index.html Edgar Link pending
0001193125-14-184864.txt Edgar Link pending
0001193125-14-184864-xbrl.zip Edgar Link pending
acad-20140331.xml Edgar Link completed
acad-20140331.xsd Edgar Link pending
acad-20140331_cal.xml Edgar Link unprocessable
acad-20140331_def.xml Edgar Link unprocessable
acad-20140331_lab.xml Edgar Link unprocessable
acad-20140331_pre.xml Edgar Link unprocessable
d690283d10q.htm Edgar Link pending
d690283dex311.htm Edgar Link pending
d690283dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending